Advancing women’s health through innovations in drug delivery

As AnelleO aims to pave the way towards bespoke treatments for women’s health with its platform technology, we needed to rethink the manufacturing approach from one-size one-dose fits all to a paradigm that enables customization. Current IVR technology is outdated and limited in its applications. AnelleO’s 3D printing technology will provide enhanced drug delivery of one or more drugs with flexible designs for better drug release and better fit. AnelleO’s first product, AnelleO PRO, will be the first IVR designed with 3D printing technology to safely and steadily release natural PROgesterone over 4 weeks to cover the entire ART period (8-10 weeks) with only 2-3 IVRs. In the US, 1.7 million women are treated annually for infertility at a cost of $3.5B. Current FDA-approved drugs for infertility are limited to daily injections, unpleasant progesterone vaginal gels or inserts with a market size for current treatments of ~$1.5B. By combining design (USPTO Patent No. 11,219,595 B2; US/EU/Canada; U.S. Provisional Patent No. 63/762,296), high speed manufacturing and therapeutic drug incorporation (PCT/US21/50949), AnelleO is on a mission to revolutionize device engineering and drug delivery for women’s health with bespoke therapies that can be easily self-administered and retrieved at home.